Controlled overexpression of selected domains of the P85 subunit of phosphatidylinositol 3-kinase reverts v-Ha-Ras transformation  by Zhang, Qun-Xing et al.
ELSEVIER Biochimica et Biophysica Acta 1312 (1996) 207-214 
Btt 
Biochi~ic~a et Biophysica ,4~ta 
Controlled overexpression of selected omains of the P85 subunit of 
phosphatidylinositol 3-kinase reverts v-Ha-Ras transformation 
Qun-Xing Zhang, Ian D. Davis, Graham S. Baldwin * 
Melbourne Tumour Biology Branch, Ludwig Institute for Cancer Research, Post Office Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia 
Received 4 September 1995; revised 1 December 1995; accepted 20 December 1995 
Abstract 
Selected domains of the regulatory p85 subunit of phosphatidylinositol 3-kinase have been expressed under the control of the 
tetracycline transactivator in NIH 3T3 fibroblasts transformed by the v-Ha-Ras oncogene. The domains expressed were the SH3 domain, 
the BCR homology domain, the region between the two SH2 domains which contains the p110 binding site (the inter SH2 (IS) domain), 
and the C-terminal (CT) domain (containing both SH2 domains and the IS domain). The levels of IS or SH3 domain expressed in the 
presence of tetracycline were sufficient o reverse the transforming effects of v-Ha-Ras, and no further inhibition of proliferation was 
observed when expression was increased 7-fold by removal of tetracycline. In contrast inhibition of proliferation by the CT domain was 
observed only when the level of expression was increased 5-fold by removal of tetracycline. Overexpression f the BCR domain of p85 
had no effect on v-Ha-Ras transformation. Expression of the IS domain disrupted the interaction of the p85 regulatory subunit with the 
p110 catalytic subunit. These results indicate that the association of the p85 subunit of PI 3-kinase with the p110 subunit is necessary for 
v-Ha-Ras-induced transformation i  NIH 3T3 cells. 
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1. Introduction 
Phosphatidylinositol (PI) 3-kinase plays an important 
role in intracellular signal transduction in pathways con- 
trolling glucose transport [1], chemotaxis [2-5] and mito- 
genesis [6-8]. Thus microinjection of antibodies against 
the catalytic subunit of PI 3-kinase inhibits DNA synthesis 
in fibroblasts in response to platelet-derived growth factor 
(PDGF) and epidermal growth factor (EGF) [8]. In addi- 
tion, mutants of the PDGF-13 receptor which lack attach- 
ment sites for PI 3-kinase are unable to support PDGF-in- 
duced DNA synthesis [6] and chemotaxis [2]. Furthermore, 
the fungal metabolite wortmannin, which is a potent and 
selective inhibitor of PI 3-kinase [5], blocks insulin-stimu- 
lated glucose transport in adipocytes [1], responses to 
chemotactic peptide in neutrophils [4,5], and nerve growth 
Abbreviations: BCR, breakpoint cluster egion; CT, carboxy terminal; 
GST, glutathione S-transferase; IS, inter SH2; MTI', (3-(4,5-dimethyl- 
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SH, src homology. 
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factor (NGF)-stimulated neurite outgrowth in PC12 cells 
[9]. Finally expression of a constitutively active PI 3-kinase 
in frog oocytes induces Ras-dependent oocyte maturation 
[10]. 
Analysis of the structure of PI 3-kinase has been funda- 
mental towards understanding its role in signal transducing 
processes. PI 3-kinase has two subunits with different 
molecular weights: p85 [l 1-13], which links the enzyme 
to activated protein tyrosine kinase receptors and other 
proteins [14], and p l l0  [15,16], which has intrinsic phos- 
phatidylinositol 3-kinase [15,16] and protein serine kinase 
activity [17,18]. The presence of several distinct functional 
domains in the p85 subunit, including a src homology 3 
(SH3) domain, a breakpoint cluster region (BCR) homol- 
ogy domain, an SH3 binding domain (proline-rich region) 
and two src homology 2 (SH2) domains suggests that the 
p85 protein may have multiple interactive and regulatory 
roles (see [19] for review). The region of the p85 protein 
necessary for binding p110 has been located between the 
two SH2 domains by deletion mapping [17,20-23]. 
The Ras protein is a GTP-binding protein that trans- 
duces signals in response to activation of receptors by their 
ligands [24]. Association of PI 3-kinase activity with the 
Ras protein has been reported [25], but the relative position 
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of Ras and PI 3-kinase in signal transduction pathways 
remains controversial. The observations that the GTP- 
bound form of Ras binds to the p110 catalytic subunit of 
PI 3-kinase, and that Ras transfection leads to elevated 
levels of 3' phosphorylated phosphoinositides in COS 
cells, are consistent with PI 3-kinase being a downstream 
target of Ras [26]. Other evidence, including the observa- 
tion that phosphorylation of the PDGF receptor at sites 
involved in the binding of p85 was required for the 
activation of Ras by PDGF [6], indicates that PI 3-kinase is 
upstream of Ras in the pathway activated by PDGF. 
However, other signalling molecules uch as Nck bind to 
the same sites on the PDGF receptor as PI 3-kinase and 
may be responsible for transduction of the signals to Ras 
[27,28]. Perhaps the clearest evidence that PI 3-kinase is 
upstream of Ras in some pathways is the recent report hat 
expression of a constitutively active PI 3-kinase induces 
Ras-dependent transcription from the fos promoter in NIH 
3T3 cells, and Ras-dependent maturation of frog oocytes 
[10]. 
To study further the role of PI 3-kinase in the Ras 
signal transduction pathway, we overexpressed various 
domains of the p85 subunit in v-Ha-Ras-transformed NIH 
3T3 cell lines. The domains selected were the SH3 do- 
main, the BCR homology domain, the C-terminal (CT) 
domain (containing both SH2 domains and the region 
between them which contains the p110 binding site), and 
the p110 binding or inter SH2 (IS) domain of PI 3-kinase. 
A repressible expression system (the tetracycline- 
responsive system of Gossen and Bujard [29]) was chosen 
because stable transfected cell lines could not be obtained 
with the pCDM8 expression vector or with a retroviral 
expression vector (Zhang and Baldwin, unpublished ata), 
presumably because of toxicity of the p85 subunit o cells 
[22,30,31]. Although overexpression f the BCR domain 
had no effect on Ras transformation, overexpression f the 
SH3 domain or the IS domain partially reversed the trans- 
formed phenotype in NIH 3T3 ceils transfected with the 
v-Ha-Ras oncogene. Our results indicated that association 
of the p85 subunit of PI 3-kinase with the p110 subunit is 
necessary for v-Ha-Ras-induced transformation of NIH 
3T3 cells. 
2. Materials and methods 
2.1. Materials 
PDGF (BB homodimer) and rabbit anti-PDGF receptor 
(13 type) polyclonal antiserum (PDGFR-3) were generous 
gifts from A. Thomasen (Amgen, Thousand Oaks, CA) 
and C.-H. Heldin (Ludwig Institute, Uppsala, Sweden) 
respectively. Rabbit anti-PI 3-kinase p85 subunit poly- 
clonal antibody was from Upstate Biotechnology (Lake 
Placid, NY). Horseradish peroxidase-conjugated goat anti- 
rabbit antibody was from Bio-Rad (Hercules, CA). Phos- 
phatidylinositol, tetracycline and hygromycin were from 
Sigma (St. Louis, MO), and geneticin was from Gibco 
(Grand Island, NY). Bovine PI 3-kinase p85 subunit cDNA 
was from M.D. Waterfield (Ludwig Institute, London, 
UK). The luciferase assay kit was from Promega (Madi- 
son, WI). The tTA system (including the plasmids 
pUHD15-1, pUHD13-3, pUHD10-3) was from M. Gossen 
and H. Bujard (Zentrum fur Molekulare Biologie, Univer- 
sitaet Heidelberg, W-6900 Heidelberg, Germany). 
The cell line expressing the v-Ha-ras oncogene, derived 
by infection of NIH 3T3 fibroblasts with a retroviral stock 
from v-Ha-Ras-transfected psi-2 cells [32], was a gift from 
G. D'Abaco, Ludwig Institute for Cancer Research, Mel- 
bourne. All cell lines were routinely passaged in Dulbecco's 
modified Eagle's (DME) medium supplemented with 10% 
fetal calf serum (Trace Scientific, Clayton, Australia). 
2.2. Construction of plasmids expressing selected omains 
of the p85 subunit 
DNA fragments containing a 5' Kozak consensus e- 
quence (GCC GCC ACC ATG), followed by the sequence 
encoding the desired domain of the p85 subunit of bovine 
PI 3-kinase [13], and a 3' termination codon (TGA), were 
Table 1 
Oligonucleotide primers used to make expression constructs 
Code Sequence Position 
SH3-S CCAGAATTCGCCGCCACCatgGCCGAGGGGGTACCA 1-20 
SH3-A AGTGGATCCtcaCCGGGGC1 HGGTGTGGGAG 251-270 
BCR-S CCAGAATrCGCCGCCACCatgCTCCCAGACCTTGCAGAGCA 342-362 
BCR-A CCAGGATCCtcaCCTCGAGATATCTCCCCAGT 1001 - 1020 
CT-S CCAGAATrCGCCGCCACCatgAATAACAATATGTCTTTACA 964-986 
CT-A AGTGGATCCtcaTCGCCTCTGCTGCGCGT 2156-2175 
IS-S CCAGAATI'CGCCGCCACCatgCCCAAACTGGATGTGAAATI'A 1252-1272 
IS-A AGT GGA TCCtcaCAAATCCTCATCATCTrCTAC 1828-1848 
Sense (S) and antisense (A) oligonucleotides were synthesized on a DNA synthesizer Model 380 A (Applied Biosystems, Foster City, CA) using 
phosphoramidite chemistry. Sequences are written in the direction 5' to 3', restriction enzyme recognition sequences are underlined, the Kozak consensus 
sequence is shown in italics, and start (atg) codons and stop (tga) codons are shown in lower case. Position numbers refer to the sequence of the bovine 
p85 subunit cDNA [13]. 
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amplified by the polymerase chain reaction and subcloned 
into pGEM-3Z. The oligonucleotide primers used to make 
the SH3, BCR, CT, and IS domain constructs are listed in 
Table 1. On sequencing in both directions one silent 
mutation was observed in the SH3 domain (Glu52(GAA) 
-~ Glu(GAG)). All constructs were then subcloned into 
the repressible xpression vector pUHD 10-3 [33,34]. 
Clones with inserts of the correct size were selected and 
DNA was prepared on a large scale using Qiagen columns 
(Qiagen, Studio City, CA). 
2.3. Transfection and selection procedure 
Cells were transfected with the calcium phosphate 
method as follows. On the day before transfection, 2.105 
cells were seeded in a 60-mm plate with 4 ml media such 
that on the day of transfection the cells were 80% conflu- 
ent. The DNA-CaC12 solution was prepared as follows: 20 
Izg linearized DNA was added to 0.2 X SSC (1.5 M NaC1, 
0.15 M sodium citrate) to a total volume of 481 Izl. 2M 
CaC12 (69 Izl) was added, followed dropwise by an equal 
volume of 2 X Hepes-buffered saline (HBS contains 280 
mM NaC1, 10 mM KCI, 1.5 mM Na2HPO4, 12 mM 
glucose, 50 mM Hepes, pH 7.05). The transfection mixture 
was then incubated at room temperature for 15-20 min 
before 0.5 ml was added to each dish. After culture for 4 h, 
the cells were shocked with 15% glycerol in 1 x HBS for 
4 min, followed by washing with DME containing 10% 
FCS twice. After washing, DME (4 ml) containing 10% 
FCS was added. The cells were incubated for a further 
24-48 h before antibiotics were added for selection. 
wash solution, and protein was detected by enhanced 
chemiluminescence (Amersham, Bucks., UK) according to 
the manufacturer's instructions. 
2.5. Northern blot analysis 
Cells were grown to confluence and placed in DME 
medium with or without etracycline (2 la, g/ml)  for 48 h, 
collected by centrifugation, homogenized in a solution 
containing 10 mM Tris HC1, pH 7.4, 0.1 M NaC1, 1 mM 
EDTA, 200 Ixg/ml proteinase K, and 0.5% NaDodSO 4
and incubated for 1 h at 37°C. mRNA was enriched by 
poly(A) ÷ selection on oligo-dT cellulose and precipitated 
with sodium acetate and ethanol, poly(A)+-mRNA (10 p,g) 
was denatured at 65°C in 2.2 M formaldehyde, 1 mM 
EDTA, 5 mM sodium acetate, 20 mM Mops, pH 7.0, 50% 
(v/v)  formamide, fractionated electrophoretically on a 1% 
(w/v)  agarose gel, and transferred onto a nylon membrane 
(GeneScreen, DuPont, Boston, MA) with 10 X SSC. The 
membrane was prehybridized at 42°C in the presence of 
50% deionized formamide, 1% dextran sulfate and 100 
I~g/ml denatured salmon sperm DNA for 4 h. The same 
solution was used for hybridization at 42°C overnight 
except that salmon sperm DNA was omitted. The 32p_ 
labelled p85 cDNA probe was denatured and added at a 
concentration of 2 × 10 6 cpm/ml. The membrane was 
washed in 2 X SSC at room temperature for 10 min, then 
twice in 2 X SSC, 1% NaDodSO 4 at 60°C for 20 min, and 
finally visualized by scanning with a phosphorirnager 
(Molecular Dynamics, Sunnyvale, CA). 
2.4. Western blot analysis 2.6. PI 3-kinase assay 
Cells were placed in DME medium with or without 
tetracycline (2 l~g/ml) for 48 h, and collected by centrifu- 
gation. The cell pellets were extracted with 200 Izl lysis 
buffer (20 mM Tris HCI, pH 8.0, 150 mM NaCI, 1% 
NP40, 10 U/ml  aprotinin, 20 IxM leupeptin, 2.5 mM 
EDTA, 10 mM NaF) and centrifuged for 10 min at 15 000 
× g. Equivalent amounts of the supernatant protein were 
boiled with sample buffer, electrophoresed on 10% or 15% 
NaDodSO4-polyacrylamide gels, and electrophoretically 
transferred to a polyvinylidene difluoride membrane (Im- 
mobilon, Millipore, Bedford, MA). The membrane was 
treated at room temperature with agitation for 1 h in 
blocking solution (PBS, 4% bovine serum albumin, 0.05% 
Tween 20), and washed twice for 5 min each in wash 
solution (PBS, 0.1% bovine serum albumin, 0.02% Tween 
20). The anti-p85 antibody was added at a 1:20000 dilu- 
tion in wash solution and incubated overnight at 4°C with 
agitation. The membrane was washed 3 times for 7 min 
each in wash solution and incubated with horseradish 
peroxidase-conjugated s cond antibody at a 1:15000 dilu- 
tion in wash solution for 1 h at room temperature with 
agitation. The membrane was agitated (3 X 20 min) in 
PI 3-kinase activity was assayed as described previously 
[35]. In brief, plasma membranes from 108 cells were 
extracted with 1 ml of lysis buffer (20 mM Hepes, pH 8.0, 
137 mM NaCl, 1 mM MgCl 2, 1 mM CaC12, 10% glycerol, 
1% NP40, 0.2 mM Na ÷ orthovanadate) for 20 min on ice 
and centrifuged for l0 min at 15,000 g to remove insoluble 
material. Immunoprecipitates were prepared from 500 I~1 
of detergent extracts with anti-PDGF receptor antibody 
and protein A-Sepharose, and washed six times as de- 
scribed previously [35]. The immunoprecipitates were then 
incubated at 25°C for 20 min in 50 I~l of l0 mM Hepes, 
pH 7.6, 100 mM NaCl, 5 mM MgC12, 1 mM EDTA, 0.2 
mg of sonicated PI (Sigma, St. Louis, MO), 5 I~M ATP, 
100 I~M Na ÷ orthovanadate, 1 mM PMSF, 200 I~M 
adenosine, and l0 txCi ['y-32p]ATP. The reaction was 
stopped with 100 I~l of 1 M HC1, protein A-Sepharose was 
removed by centrifugation, and phospholipids were ex- 
tracted and analysed by thin-layer chromatography on 
potassium oxalate-treated silica gel plates with chloro- 
form/methanol/4M NH4OH (9 /4 /2 ,  by vol) as solvent. 
Labelled PI 3-phosphate was visualized and quantitated by 
phosphorimager scanning. 
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2.7. Measurement ofcell growth rate 
Cell growth rate was measured as described by Mos- 
mann [36]. Briefly, adherent cells were harvested with 
0.1% (w/v)  trypsin in 0.2 mg/ml  EDTA at 37°C for 5-10 
min. Cells were washed once in PBS and plated at a 
density of 1 × 10 3 cells in 96-well plates containing 200 
Ixl medium with and without tetracycline (2 p~g/ml) per 
well. At the indicated times 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT) (10 I~1 of 5 
mg/ml  in PBS) was added and incubated for 4 h at 37°C. 
The medium was carefully discarded and 200 i~1 of acidi- 
fied isopropanol (20 ml 1M HC1 in 500 ml isopropanol) 
was added to each well. The plate was shaken for 10 min 
and the absorbance of the wells at 560 nm was determined 
on a Titertek Multiscan platereader (Labsystem, Helsinki, 
Finland). 
2.8. Assay for colony-forming ability in soft agar 
The soft agar transformation assay was carried out as 
described by Maruta and coworkers [37]. 0.5% base agar 
was prepared by melting 1% bacto agar in a microwave, 
cooling to 40°C in a waterbath, mixing with an equal 
volume of 2 × RPMI medium containing 20% FCS pre- 
warmed to 40°C, and adding 1.5 ml of the mixture to each 
35 mm petri dish. Top agar was prepared by melting 0.7% 
bacto agar, cooling to 40°C, and mixing with 2 × RPMI 
medium containing 20% FCS prewarmed to 40°C. 1 × 10 3 
cells were added to 3 ml top agar mixture with and without 
tetracycline (2 i~g/ml) prior to plating in a petri dish 
containing base agar. The dishes were incubated at 37°C 
for 18 days before colonies were scored. 
3. Results 
v-Ha-Ras-transformed NIH 3T3 cell lines expressing 
different p85 domains were derived as follows. The plas- 
mid pUHD 15-1, which expresses the tetracycline transac- 
tivator [29], was transfected into v-Ha-Ras transformed 
NIH3T3 cells using the G418 resistance gene as a cotrans- 
fection marker. Stably transfected cell clones were selected 
with geneticin and tested for expression of the transactiva- 
tor by screening for luciferase activity after transient trans- 
fection with the plasmid pUHD 13-3 which carries the 
luciferase gene. Luciferase activity in these cell lines could 
be induced 15-fold by removal of tetracycline (data not 
shown). 
Stable cell clones containing the plasmid pUHD 15-1 
were then co-transfected with the expression plasmid 
pUHD 10-3 containing various fragments of p85 cDNA 
and a hygromycin resistance gene vector in the presence of 
2 txg/ml tetracycline. Hygromycin-resistant cell lines were 
screened by Western or Northern blotting for tetracycline- 
dependent overexpression of the SH3, BCR, CT and IS 
domains of p85. The increase in expression on removal of 
tetracycline was 8-fold for the SH3 domain, 7-fold for the 
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Fig. 1. Overexpression f selected p85 domains, v-Ha-Ras-transformed N1H3T3 cells harbouring plasmids containing the cDNAs encoding the BCR (A), 
CT (A), SH3 (B), or IS domains (C) or vector alone (A, C) were grown in the presence (+)  or absence ( - )  of 2 I~g/ml tetracycline. Aliquots were 
subjected to NaDodSOa-polyacrylamide g l electrophoresis on 12.5% (A) or 10% (B) gels, and Western blotted with an antibody recognizing epitopes of 
p85 outside the IS domain as described in the Materials and Methods section. Bound antibody was detected by enhanced chemiluminescence, and 
quantitated by densitometry. Because of the unavailability of an antibody recognizing the IS domain, mRNA was prepared, subjected to electrophoresis on 
a 1% agarose gel, and probed sequentially (C) with p85 cDNA and with glyceraldehyde 3-phosphate d hydrogenase (GAPDH) cDNA. Bound radioactivity 
was quantitated by phosphorimager. Levels of p85 domains (D-E) were expressed relative to the amount of endogenous p85 protein. Since endogenous p85 
mRNA was not detected, levels of IS domain mRNA (F) were expressed relative to GAPDH. Sizes of protein and RNA standards are given in kDa and kb, 
respectively. Results are representative of at least three separate xperiments. 
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BCR domain and 5-fold for the CT domain (Fig. 1A, B). 
Because of unavailability of an antibody which could 
recognise the IS domain, Northern blotting was used to 
screen the clones transfected with the IS domain cDNA 
(Fig. 1C). There was a 7-fold increase in IS domain 
mRNA expression after induction. Although all clones 
displayed high level expression of various p85 domains in 
the absence of tetracycline,, expression of all domains was 
also detected in the presence of tetracycline. 
In order to test whether overexpression of the IS do- 
main disrupted the interaction of the p85 regulatory sub- 
unit with the p l l0  catalytic subunit, association of PI 
3-kinase with the PDGF receptor was measured following 
PDGF stimulation. Cell lines expressing the IS domain 
were grown in the presence or absence of tetracycline, 
treated with PDGF, and then lysed. PI 3-kinase activity 
was then analysed in immunoprecipitates prepared with an 
antibody recognizing epitopes of the p85 subunit outside 
A 
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PDGF 
PIP 
ORI 
g 
j 
÷ + 
÷ ÷ -F 
i 
the IS domain or with an antibody recognizing the PDGF-[3 
receptor. The levels of IS domain expressed in the pres- 
ence of tetracycline were sufficient o block the association 
of PI 3-kinase activity with the p85 regulatory subunit 
(data not shown), and with the activated PDGF receptor 
(Fig. 2). 
The growth rate of v-Ha-Ras-transformed NIH3T3 cells 
expressing low levels of the SH3 or IS domains in the 
presence of tetracycline was decreased, compared with 
vector-only transfected cells (Fig. 3A). In contrast, low 
level expression of the BCR or CT domains did not reduce 
the growth rate. When the levels of CT domain expression 
were increased by removal of tetracycline, the growth rate 
decreased markedly (Fig. 3B). In contrast, little or no 
further decrease in the growth rate of cells which ex- 
pressed the SH3 or IS domains was observed on removal 
of tetracycline. 
v-Ha-ras transformed NIH 3T3 cells which overex- 
pressed the SH3, the CT, or the IS domains became 
morphologically fiat like normal NIH3T3 fibroblasts and 
formed foci rarely or not at all even when the cells became 
overconfluent (Fig. 4). In contrast, the vector-only trans- 
fected v-Ha-ras-transformed c lls or cells transfected with 
the BCR domain formed many foci even when the cells 
had reached only 80% confluence. 
In order to test whether the different domains of p85 
were able to reverse the clonogenic effects of v-Ha-ras in 
mammalian cells, the effect of overexpression f selected 
domains on colony-forming ability in soft agar was exam- 
ined. Overexpression of the SH3, the CT, or the IS do- 
mains greatly reduced colony formation of v-Ha-ras 
NIH3T3 cells, compared with the vector-only transfected 
v-Ha-ras cells (Table 2), whereas overexpression of the 
BCR domain did not change the colony formation of 
v-Ha-ras cells in soft agar. 
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Fig. 2. Overexpression f the IS domain reduces PDGF receptor-associ- 
ated PI 3-kinase activity. Serum.starved v-Ha-Ras-transformed NIH3T3 
cells expressing either vector only or vector containing the IS domain 
were incubated with or without PDGF-BB (100 ng/ml)  and tetracycline 
(Tet, 2 p,g/ml) for 15 min at 37°C. Immunoprecipitates were prepared 
from detergent extracts of crude plasma membranes with antibodies to the 
PDGF receptor, and assayed for PI 3-kinase activity as described in the 
Materials and Methods section. PI 3-phosphate (PIP) was separated by 
thin layer chromatography, and quantitated by scanning with a phospho- 
rimager. The other major reaction product (Rf = 0.6) is likely to be 
PI-3,4-diphosphate (Rf = 0.6 [38]), formed by the action of PI 3-kinase 
on PI-4-phosphate present as a contaminant in the sample of PI. ORI: 
origin. A: Phosphorimager scan; B: Quantitation of PI 3-phosphate using 
Imagequant software. Values were expressed as a percentage of the value 
obtained in unstimulated cells transfected with the vector only. 
4. Discussion 
Studies with antibodies, growth factor receptor mutants 
and selective inhibitors have indicated the importance of 
the PI 3-kinase pathway in the control of glucose transport, 
chemotaxis and mitogenesis [19]. However, studies with 
mutants in particular cannot exclude the possibility that 
other signalling molecules may bind to the same sites on 
the receptor as PI 3-kinase and actually transduce the 
signals [27,28]. One alternative approach is to generate by 
transient [16,23,31,38,39] or stable [22,30,40] transfection 
cell lines which constitutively express high levels of p85, 
or of the different domains of p85. However some p85 
domains appear to be toxic to mammalian cell lines when 
expressed in large amounts [22,30,31]. We therefore m- 
ployed a repressible xpression system to overexpress the 
SH3, BCR, CT and IS domains of the p85 subunit of PI 
3-kinase in v-Ha-Ras-transformed NIH 3T3 cells. As well 
as avoiding toxicity problems the tetracycline-repressible 
E ¢.- 
o 
o 
,0 B 
E 0.8 
g 0.6 
g 0.4 
0.2 
0.0 
1.0 A 
0.8 
0.6 
0.4 
0.2 
0.0 
~yl  day2 ~y3 ~y4 
212 Q.-X. Zhang et aL / Biochimica et Biophysica Acta 1312 (1996) 207-214 
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Fig. 3. Effect of expressing different p85 domains on proliferation. 
Proliferation of v-Ha-Ras-transformed N]~3T3 cells expressing the indi- 
cated domains of the p85 subunit of PI 3-kinase was measured in the 
presence (A) and absence (B) of tetracycline by the MTT assay as 
described in the Materials and Methods ection. Values are the means of 
6 samples and bars represent 1 SD. Statistical significance r lative to the 
vector-only control was assessed by Student's t-test. *, P < 0.01; * *, 
P < 0.001. 
Vector only 
SH 3 
CT 
BCR 
IS 
Fig. 4. Morphological changes in v-Ha-Ras-transforn~d NIH3T3 cells 
expressing different p85 domains, v-I-la-Ras-transformed NIH3T3 cells 
expressing the indicated omains of the p85 subunit of PI 3-kinase were 
grown without etracycline in DME medium containing 10% FCS until 
confluent. Magnification: 80 ×. 
Table 2 
SH3, CT and IS domains inhibit colony formation by v-Ha-Ras-trans- 
formed NIH 3T3 cells 
p85 domain Colony number 
Without Tet With Tet 
none (vector only) 740 + 190 730 4- 189 
SH3 67 4- 11 75 4- 27 
BCR 679 4- 207 580 4- 115 
CT 554- 25 169+ 77 
IS 774- 57 1444- 106 
103 v-Ha-Ras-transformed NIH 3T3 cells expressing the indicated o- 
main of the p85 subunit of PI 3-kinase were plated in soft agar as 
described in Section 2. Mean colony numbers (4-SD) in two separate 
experiments were measured 18 days later. 
system allowed comparison of the behavior of the same 
genetically homogeneous clones under repressed and non- 
repressed conditions, eliminating the factors of clonal vari- 
ation and allowing quantitative assessment of the functions 
of different domains. 
Expression of the IS domain of the p85 subunit of PI 
3-kinase in v-Ha-Ras-transformed NIH 3T3 cells disrupted 
the association of the regulatory p85 subunit with the 
catalytic p l l0  subunit. Disruption could be demonstrated 
by a reduction in PI 3-kinase assay in immunoprecipitates 
prepared with either anti-p85 antibodies or with anti-PDGF 
receptor antibodies after PDGF receptor activation by 
PDGF stimulation (Fig. 2). These effects were observed 
even with the relatively low levels of expression observed 
in the presence of tetracycline. A similar reduction in the 
levels of PI 3-kinase activity associated with the activated 
PDGF receptor has been observed in human embryonic 
kidney fibroblasts transiently expressing either the IS do- 
main or an N-terminal fragment of p110 [31]. Overexpres- 
sion of the IS domain of the p85 subunit also reverted 
transformed morphology, inhibited focus formation and 
colony formation in soft agar, and decreased growth rate. 
The simplest explanation for these observations i that the 
association of the two subunits of PI 3-kinase is essential 
for maintenance of v-Ha-Ras-induced transformation in 
NIH 3T3 cells. 
These observations are consistent with previous reports 
that intersubunit contact regulates PI 3-kinase activity. The 
p l l0  protein purified from bovine thymus is 5-fold more 
active than the p85-pl10 complex from the same source 
[41]. In contrast, although expression of p l l0  subunits 
alone results in PI 3-kinase activity in insect cells, co-ex- 
pression with p85 is required for activity in mammalian 
ceils [10,15,23]. The PI 3-kinase activity of a fusion 
protein in which the IS domain of p85 was covalently 
linked to p l l0  was also significantly greater that the 
activity of wild-type p110 coexpressed with the IS domain 
[10]. Furthermore phosphotyrosine-containing proteins or 
peptides cause enzyme activation by binding to the SH2 
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domains of p85 [21,42,43]. Although the mechanism for 
activation appears to be a phosphopeptide-induced confor- 
mational change in p85 [44,45], the influence of this 
structural change on p l l0  remains unclear. PI 3-kinase 
activity was also increased by binding of SH3 domains to 
the proline-rich region of p85 [46], or by binding of 
GTP-bound forms of small G-proteins to the BCR domain 
of p85 [47,48]. p85 could therefore serve as a point of 
convergence for diverse signals in regulating PI 3-kinase, 
and hence disruption of the intersubunit association could 
reduce PI 3-kinase activity. 
Overexpression of the CT domain also had profound 
effects in cell proliferation and transformation assays. The 
relatively low levels of CT expression observed in the 
presence of tetracycline (Fig. 1) had no significant effect 
on cell proliferation (Fig. 3), but did suppress colony 
formation in soft agar (Table 2). The higher levels of CT 
expression achieved in the absence of tetracycline inhib- 
ited both cell proliferation (Fig. 3), colony formation in 
soft agar (Table 2), and focus formation (Fig. 4). These 
differences are not altogether surprising, since the assays 
measure fundamentally different processes. Thus the MTT 
assay measures mitochondrial oxidation, which is an index 
of cell number [36]. On the other hand focus formation and 
soft agar colony formation measure the ability of a cell 
line to overcome contact inhibition and anchorage depen- 
dence respectively, and have been used as indices of cell 
transformation. OUr data therefore suggest hat cell trans- 
formation is more sensitive to overexpression f the CT 
domain than cell proliferation. 
The effects of expression of the CT domain on cell 
proliferation differed from the effects of the IS domain. In 
contrast o IS domain expression, which inhibited cell 
proliferation at both low and high levels, expression of low 
levels of the CT domain had no effect on cell proliferation 
(Fig. 3). The extra SH2 domains present in the CT frag- 
ment may provide one possible explanation for this differ- 
ence. Binding of phosphotyrosine-containing proteins or 
peptides to the SH2 domains of p85 has been shown to 
activate the PI 3-kinase activity associated with the p l l0  
subunit [21,42,43]. If similar activation were to occur 
through the SH2 domains of the CT fragment, then low 
concentrations of the CT fragment might substitute for p85 
in signal transduction between phosphotyrosine-containing 
proteins and p110. At high concentrations the CT fragment 
might bind independently to both the phosphotyrosine- 
containing proteins and pl l0,  and hence disrupt signal 
transduction. In contrast he IS domain cannot couple to 
other molecules, but can act as an inhibitor of signalling 
via p110, by competition with p85 for binding to p110. 
Recent evidence indicates an involvement of the SH3 
domain in both positive and negative regulation of cell 
growth and transformation. For example, deletion or muta- 
tion of SH3 domains activates the transforming potential 
of nonreceptor tyrosine kinases, suggesting involvement in
negative regulation of an intrinsic transforming activity of 
such proteins [49,50]. In the case of p85 the SH3 domain 
may also play an important role in cytoskeletal interactions 
since binding of the SH3 domain of p85 to dynamin 
activates the GTPase activity of dynamin [51]. Overexpres- 
sion of the SH3 domain of p85 also reverted v-Ha-Ras- 
transformed NIH 3T3 cell morphology to a relatively fiat 
state (Fig. 4), decreased growth rate and inhibited colony 
formation in soft agar. Although further experiments with 
other SH3 domains will be required to explore the speci- 
ficity of inhibition, to our knowledge this is the first time 
that any SH3 domain has been found to inhibit v-Ha-Ras 
transformation. 
The results presented in this paper emphasize yet again 
the difficulties inherent in defining signalling pathways. 
Current evidence suggests that PI 3-kinase is upstream of 
Ras in pathways leading to fos trancription and oocyte 
maturation [10]. However Ras must also exert reciprocal 
effects on PI 3-kinase, since transfection of Ras into COS 
cells results in increased levels of 3'-phosphorylated phos- 
phoinositides [26]. Our data suggest that another pathway, 
in which PI 3-kinase is downstream of Ras, may be 
involved in v-Ha-Ras transformation. One possible model 
for this additional pathway, consistent with the previous 
report that Ras in the active GTP-bound state binds di- 
rectly to the p110 subunit of PI 3-kinase in vitro [26], and 
with our observations that overexpression f IS and SH3 
domains reverses v-Ha-Ras transformation, is as follows. 
Activated Ras binds to the p110 subunit of PI 3-kinase, 
which in turn binds to a downstream olecule(s) through 
the SH3 domain of the p85 subunit. In this model overex- 
pression of the IS domain would block Ras signalling by 
disrupting the association of the two subunits, while the 
overexpressed SH3 domain would compete with the SH3 
domain of p85 for binding to an unknown downstream 
molecule(s). Future work will concentrate on the identity 
of the downstream olecule, and hence on the function of 
the SH3 domains of p85 in Ras transformation. 
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